The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LMAT | +4.12% | +187.67% | +23.53% | +1,623% |
| S&P | +14.5% | +93.32% | +14.09% | +390% |
LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA.
The healthcare company's dividend has soared in recent years.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $64.23M | 15.0% |
| Gross Profit | $43.54M | 17.7% |
| Gross Margin | 67.78% | 1.5% |
| Market Cap | $1.88B | 1.6% |
| Market Cap / Employee | $2.83M | 0.0% |
| Employees | 664 | 5.4% |
| Net Income | $13.78M | 16.5% |
| EBITDA | $18.79M | 12.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $27.18M | 22.0% |
| Accounts Receivable | $36.54M | 18.5% |
| Inventory | 57.5 | 1.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $183.06M | 1057.3% |
| Short Term Debt | $2.83M | 9.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 10.02% | -0.9% |
| Return On Invested Capital | 8.98% | -0.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $18.95M | 144.6% |
| Operating Free Cash Flow | $20.29M | 110.8% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 50.95 | 47.62 | 42.43 | 40.34 | -18.18% |
| Price to Book | 6.31 | 6.26 | 5.61 | 5.40 | -9.82% |
| Price to Sales | 9.96 | 9.60 | 8.49 | 8.10 | -10.90% |
| Price to Tangible Book Value | 9.17 | 9.09 | 8.03 | 7.59 | -16.85% |
| Price to Free Cash Flow TTM | 108.24 | 92.62 | 74.43 | 52.68 | -48.52% |
| Enterprise Value to EBITDA | 129.43 | 130.18 | 118.86 | 94.07 | -11.16% |
| Free Cash Flow Yield | 0.9% | 1.1% | 1.3% | 1.9% | 94.26% |
| Return on Equity | 13.3% | 13.9% | 13.8% | 13.8% | 10.59% |
| Total Debt | $18.33M | $185.69M | $185.36M | $185.89M | 909.77% |
LMAT earnings call for the period ending August 31, 2021.
LMAT earnings call for the period ending June 30, 2021.
LMAT earnings call for the period ending March 31, 2021.
LMAT earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
